+

WO1999040073A3 - Tryptase-inhibitoren - Google Patents

Tryptase-inhibitoren Download PDF

Info

Publication number
WO1999040073A3
WO1999040073A3 PCT/EP1999/000727 EP9900727W WO9940073A3 WO 1999040073 A3 WO1999040073 A3 WO 1999040073A3 EP 9900727 W EP9900727 W EP 9900727W WO 9940073 A3 WO9940073 A3 WO 9940073A3
Authority
WO
WIPO (PCT)
Prior art keywords
tryptase
inhibitors
different
same
group
Prior art date
Application number
PCT/EP1999/000727
Other languages
English (en)
French (fr)
Other versions
WO1999040073A2 (de
Inventor
Wolfram Bode
Luis Moroder
Pedro Jose Barbosa Pereira
Andreas Bergner
Robert Huber
Christian Sommerhoff
Norbert Schaschke
Thomas Baer
Thomas Martin
Josef Stadlwieser
Wolf-Ruediger Ulrich
Andreas Dominik
Ulrich Thibaut
Daniela Bundschuh
Rolf Beume
Karl-Josef Goebel
Original Assignee
Max Planck Gesellschaft
Byk Gulden Lomberg Chem Fab
Wolfram Bode
Luis Moroder
Pedro Jose Barbosa Pereira
Andreas Bergner
Robert Huber
Christian Sommerhoff
Norbert Schaschke
Thomas Baer
Thomas Martin
Josef Stadlwieser
Ulrich Wolf Ruediger
Andreas Dominik
Ulrich Thibaut
Daniela Bundschuh
Rolf Beume
Goebel Karl Josef
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19851300A external-priority patent/DE19851300A1/de
Application filed by Max Planck Gesellschaft, Byk Gulden Lomberg Chem Fab, Wolfram Bode, Luis Moroder, Pedro Jose Barbosa Pereira, Andreas Bergner, Robert Huber, Christian Sommerhoff, Norbert Schaschke, Thomas Baer, Thomas Martin, Josef Stadlwieser, Ulrich Wolf Ruediger, Andreas Dominik, Ulrich Thibaut, Daniela Bundschuh, Rolf Beume, Goebel Karl Josef filed Critical Max Planck Gesellschaft
Priority to EP99907497A priority Critical patent/EP1060171A2/de
Priority to US09/601,318 priority patent/US6613769B1/en
Priority to JP2000530503A priority patent/JP2002502845A/ja
Priority to AU27230/99A priority patent/AU2723099A/en
Publication of WO1999040073A2 publication Critical patent/WO1999040073A2/de
Publication of WO1999040073A3 publication Critical patent/WO1999040073A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die Erfindung betrifft bifunktionelle Inhibitoren von humaner Tryptase der Formel (I), humane Tryptase in kristallisierter Form, ein Verfahren zur Herstellung von humaner Tryptase in kristallisierter Form, pharmazeutische Zusammensetzungen, umfassend einen bifunktionellen Inhibitor von humaner Tryptase sowie ein Verfahren zur Entwicklung und Identifizierung von Tryptase-Inhibitoren, dadurch gekennzeichnet, dass die beiden Kopfgruppen K1 und K2 gleich oder verschieden sind und jeweils eine Gruppe Q umfassen, die mit einer Carboxylatgruppe Wechselwirkungen eingehen kann, der Linker L eine Konformation einnehmen kann, so daß die Gruppen Q der beiden Kopfgruppen in einem Abstand von 20 bis 45 Å vorliegen, die Ausmaße der Kopfgruppen und des Linkers das Eindringen des Inhibitors in einen Hohlraum mit den Dimensionen 52 Å x 32 Å x 40 Å erlauben, und L für die Formel (II) steht, worin A1 und A2 gleich oder verschieden sind und -C(O)-, -NH-, -O- (Sauerstoff), -S- (Schwefel), -S(O)2-, -S(O)2-NH-, -NH-S(O)2-, -C(O)-NH-, -NH-C(O)-, -O-C(O)-, -C(O)-O- oder eine Bindung bedeuten, A3 und A4 gleich oder verschieden sind und -C(O)-, -C(S)-, -O-, -S-, -NH-, -O-C(O)-, -C(O)-O-, -C(O)-NH-, -NH-C(O)- oder eine Bindung bedeuten, oder ausgewählt sind aus der Gruppe A5, A6, M, B1-B6 wie in der Beschreibung.
PCT/EP1999/000727 1998-02-06 1999-02-04 Tryptase-inhibitoren WO1999040073A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99907497A EP1060171A2 (de) 1998-02-06 1999-02-04 Tryptase-inhibitoren
US09/601,318 US6613769B1 (en) 1998-02-06 1999-02-04 Tryptase inhibitors
JP2000530503A JP2002502845A (ja) 1998-02-06 1999-02-04 トリプターゼ阻害物質
AU27230/99A AU2723099A (en) 1998-02-06 1999-02-04 Tryptase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19804761 1998-02-06
DE19851300.3 1998-11-06
DE19804761.4 1998-11-06
DE19851300A DE19851300A1 (de) 1998-02-06 1998-11-06 Tryptase-Inhibitoren

Publications (2)

Publication Number Publication Date
WO1999040073A2 WO1999040073A2 (de) 1999-08-12
WO1999040073A3 true WO1999040073A3 (de) 1999-11-11

Family

ID=26043653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/000727 WO1999040073A2 (de) 1998-02-06 1999-02-04 Tryptase-inhibitoren

Country Status (5)

Country Link
US (1) US6613769B1 (de)
EP (1) EP1060171A2 (de)
JP (1) JP2002502845A (de)
AU (1) AU2723099A (de)
WO (1) WO1999040073A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1244643B1 (de) 1999-12-20 2004-06-16 ALTANA Pharma AG Tryptase-inhibitoren
AU783371B2 (en) 1999-12-20 2005-10-20 Altana Pharma Ag Tryptase inhibitors
EP1358182B1 (de) 2001-01-31 2004-08-11 ALTANA Pharma AG Diazocinderivate und deren verwendung als tryptase inhibitoren
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
WO2002066420A2 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
DE60216920T2 (de) * 2001-06-19 2007-11-15 Nycomed Gmbh Tryptase-inhibitoren
JPWO2003011812A1 (ja) * 2001-08-01 2004-11-18 持田製薬株式会社 ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬
AU2003252355A1 (en) * 2002-08-01 2004-02-23 Mochida Pharmaceutical Co., Ltd. Novel crystalline tryptase and utilization thereof
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
RU2444362C2 (ru) 2005-12-05 2012-03-10 Оцука Фармасьютикал Ко., Лтд. Лекарственное средство
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
WO1997037969A1 (fr) * 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Inhibiteur de tryptase derives de guanidino
WO1998004537A1 (en) * 1996-07-30 1998-02-05 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1060175B1 (de) * 1998-02-06 2004-11-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
WO1997037969A1 (fr) * 1996-04-10 1997-10-16 Ono Pharmaceutical Co., Ltd. Inhibiteur de tryptase derives de guanidino
EP0893437A1 (de) * 1996-04-10 1999-01-27 Ono Pharmaceutical Co., Ltd. Tryptase-Inhibitor und Guanidino-Derivate
WO1998004537A1 (en) * 1996-07-30 1998-02-05 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity

Also Published As

Publication number Publication date
US6613769B1 (en) 2003-09-02
AU2723099A (en) 1999-08-23
WO1999040073A2 (de) 1999-08-12
JP2002502845A (ja) 2002-01-29
EP1060171A2 (de) 2000-12-20

Similar Documents

Publication Publication Date Title
WO1999040073A3 (de) Tryptase-inhibitoren
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
ITTO20000303A0 (it) Procedimento per l'animazione di un modello sintetizzato di volto umano pilotata da un segnale audio.
TW427996B (en) Novel triazolopyrimidines and their use as medicaments
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
BR0010209A (pt) Composições para o tratamento de desordens do esÈfago
CA2303828A1 (en) Chewing gum containing physiological cooling agents
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
CA2233315A1 (en) Pharmaceutical compositions containing hydroximic acid derivatives
CA2412047A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
DK0579996T3 (da) 5,10-Methylentetrahydrofolsyrecyclodextrin-inklusionsforbindelser
IL112020A0 (en) Arylacetic acid derivatives, their preparation and their use as fungicides
WO1993010742A3 (en) Chemical compounds, their preparation and use
EP0931545A3 (de) Droloxifen pharmazeutische Zusammenstellung
ATE187334T1 (de) Pharmazeutische zusammensetzung in form eines gels mit chondroitinsulfat in salzform zur oralen verabreichung
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
FR2705346B1 (fr) Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
GEP20032924B (en) Novel Furan Diarylmethylidene Derivatives, Method for Their Preparation and Pharmaceutical Composition
EP0722339A4 (de) IMPFSTÄMME DER SEROGRUPPE 01 (CVD111) UND NICHT-01 (CVD112 UND CVD112RM) VON -i(VIBRIO CHOLERAE) UND METHODEN IHRER HERSTELLUNG
DK0497978T3 (da) Cephalosporinforbindelser og fremstilling heraf.
DE3667914D1 (de) Entzuendungshemmende zusammensetzungen und verfahren.
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
HUP9801750A2 (hu) Vízoldható B-polimixin-konjugátumok, eljárás azok előállítására és ilyen konjugátumokat tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999907497

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999907497

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09601318

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999907497

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载